The Effect of DA-9701 in Opioid-induced Bowel Dysfunction of Guinea Pig = The Effect of DA-9701 in Opioid-induced Bowel Dysfunction of Guinea Pig

다국어 초록 (Multilingual Abstract)

Background/Aims Opioid induced bowel dysfunction (OIBD) is associated with decreased gastrointestinal (GI) propulsive activity due to intake of opioid analgesics. DA-9701, a novel prokinetic agent formulated with Pharbitis Semen and Corydalis Tuber has promising effects on GI motor function. Therefore, we aim to evaluate the prokinetic effects of DA-9701 in an OIBD model of guinea pig. Methods The ileal and distal colon muscle contraction in presence of different doses of DA-9701, morphine, and combination (morphine + DA- 9701) was measured by tissue bath study. The prokinetic effect of DA-9701 was assessed by charcoal transit and fecal pellet output assay in an OIBD model of guinea pig. Results DA-9701 significantly increased the amplitude and area under the curve of ileal muscle contraction, while there was insignificant effect on the distal colon compared to the control. The maximal amplitude of ileal muscle contraction was acquired at a concentration of 10 μg/mL of DA-9701. In contrast, morphine significantly decreased the amplitude of ileal and distal colon muscle contraction compared to the control. Morphine delayed both upper (P < 0.01) and lower (P < 0.05) GI transit, and delayed GI transit was restored by the administration of DA-9701. Morphine induced reduction of contractility was significantly ameliorated by addition of DA-9701 in both ileal and distal colon muscles. Conclusions DA-9701 significantly increased the amplitude of contraction of the ileal muscle, however the distal colon muscle contraction was insignificant. Additionally, it restored delayed upper and lower GI transit in an OIBD model of guinea pig, and it might prove to be a useful candidate drug in a clinical trial for OIBD. (J Neurogastroenterol Motil 2016;22:529-538)

참고문헌 (Reference)

1 Holzer P, "Treatment of opioid-induced gut dysfunction" 16 : 181-194, 2007

2 Bell TJ, "The prevalence, severity, and impact of opioid-induced bowel dysfunction:results of a US and European patient survey (PROBE 1)" 10 : 35-42, 2009

3 Davis MP, "The opioid bowel syndrome: a review of pathophysiology and treatment" 1 : 153-161, 2005

4 Lee TH, "Tetrahydroberberine, an isoquinoline alkaloid isolated from corydalis tuber, enhances gastrointestinal motor function" 338 : 917-924, 2011

5 Holzer P, "Opioids and opioid receptors in the enteric nervous system:from a problem in opioid analgesia to a possible new prokinetic therapy in humans" 361 : 192-195, 2004

6 Panchal SJ, "Opioid-induced bowel dysfunction: prevalence, pathophysiology and burden" 61 : 1181-1187, 2007

7 Kurz A, "Opioid-induced bowel dysfunction: pathophysiology and potential new therapies" 63 : 649-671, 2003

8 Bianchi G, "Morphine tissue levels and reduction of gastrointestinal transit in rats. Correlation supports primary action site in the gut" 85 : 852-858, 1983

9 Reimer K, "Meeting the challenges of opioidinduced constipation in chronic pain management - a novel approach" 83 : 10-17, 2009

10 Fei G, "Lubiprostone reverses the inhibitory action of morphine on intestinal secretion in guinea pig and mouse" 334 : 333-340, 2010

11 De Luca A, "Insights into opioid action in the intestinal tract" 69 : 103-115, 1996

12 Pappagallo M, "Incidence, prevalence, and management of opioid bowel dysfunction" 182 (182): 11S-18S, 2001

13 Lee TH, "Gastroprokinetic effects of DA-9701, a new prokinetic agent formulated with Pharbitis Semen and Corydalis Tuber" 15 : 836-843, 2008

14 Wood JD, "Function of opioids in the enteric nervous system" 16 (16): 17-28, 2004

15 Sloots CE, "Efficacy and safety of prucalopride in patients with chronic noncancer pain suffering from opioid-induced constipation" 55 : 2912-2921, 2010

16 Lee TH, "Effects of corydaline from Corydalis tuber on gastric motor function in an animal model" 33 : 958-962, 2010

17 Kim ER, "Effects of DA-9701, a novel prokinetic agent, on gastric accommodation in conscious dogs" 27 : 766-772, 2012

18 Lim CH, "Effect of DA-9701on gastric emptying in a mouse model: assessment by 13C-octanoic acid acid breath test" 19 : 4380-4385, 2013

19 Jung YS, "Effect of DA-9701, a novel prokinetic agent, on stress-induced delayed gastric emptying and hormonal changes in rats" 25 : 254-259, 2013

20 Hung TM, "Cholinesterase inhibitory and antiamnesic activity of alkaloids from Corydalis turtschaninovii" 119 : 74-80, 2008

21 Hung TM, "Anti-amnestic activity of pseudocoptisine from Corydalis Tuber" 31 : 159-162, 2008

22 Webster L, "Alvimopan, a peripherally acting mu-opioid receptor (PAM-OR) antagonist for the treatment of opioidinduced bowel dysfunction: results from a randomized, double-blind, placebo-controlled, dose-finding study in subjects taking opioids for chronic non-cancer pain" 137 : 428-440, 2008